Latest Biotechnology, Pharmaceutical and Healthcare News from Astellas Pharma Inc.

21:10 EST 16th February 2019 | BioPortfolio

Here are the most relevant search results for "Astellas Pharma Inc." found in our extensive news archives from over 250 global news sources.

More Information about Astellas Pharma Inc. on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Astellas Pharma Inc. for you to read. Along with our medical data and news we also list Astellas Pharma Inc. Clinical Trials, which are updated daily. BioPortfolio also has a large database of Astellas Pharma Inc. Companies for you to search.

Showing News Articles 1–25 of 121 from Astellas Pharma Inc.

Friday 16th February 2018

Astellas Launches Global Campaign in Collaboration with CNN as Part of Global Corporate Brand Activity

Wednesday 14th February 2018

Astellas Acquires Universal Cells, Inc.

Astellas Partners with Discovery Communications for its Global Branding Campaign

Thursday 8th February 2018

Astellas Announce Top-Line Results for Two Phase 3 Trials of Peficitinib in Rheumatoid Arthritis Patients with Inadequate Response to Existing Therapy(pdf 249 KB)

Tuesday 6th February 2018

Phase 3 PROSPER Trial Shows XTANDI (enzalutamide) Significantly Reduced the Risk of Metastasis or Death by 71 Percent in Men with Non-Metastatic Castration-Resistant Prostate Cancer (pdf 531KB)

Monday 5th February 2018

Astellas Announces Changes in Management Structure, Global Function, and Top Management Committees (pdf 200KB)

Astellas Announces Personnel Changes and Organizational Changes (pdf 305KB)

Wednesday 31st January 2018

Astellas Appoints Kenji Yasukawa as President and CEO

Astellas Announces Transition to a Company with an Audit & Supervisory Committee (pdf 242KB)

Astellas Announces Acquisition of Own Shares (pdf 119KB)

Astellas Reports Financial Results for the First Nine Months of FY2017 (pdf 145KB)

Monday 29th January 2018

Astellas to Present New Oncology Data at the 2018 ASCO Genitourinary Cancers (GU) Symposium (pdf 143KB)

Wednesday 24th January 2018

Astellas Completes Acquisition of Mitobridge, Inc. (pdf 242KB)

Tuesday 23rd January 2018

Astellas Receives Orphan Designation from the European Commission for Gilteritinib for the Treatment of Acute Myeloid Leukaemia (pdf 377KB)

Monday 22nd January 2018

Astellas and Vical Announce Top-Line Results for Phase 3 Trial of Cytomegalovirus Vaccine ASP0113 in Hematopoietic Stem Cell Transplant Recipients (pdf 359KB)

Friday 12th January 2018

Repatha® SC Injection 420 mg Auto Mini Doser Launched in Japan (pdf 583KB)

Thursday 11th January 2018

Astellas Submits Supplemental New Drug Application for Approval of Additional Indication of Selective SGLT2 Inhibitor Ipragliflozin L-Proline for Patients with Type 1 Diabetes Mellitus in Japan

Tokyo and City, January 11, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas” ) and Kotobuki Pharmaceutical Co., Ltd. (President and CEO; Hiroshi Tomiyama, “Kotobuki”) today announced that Astellas submitted an application for the additional indication of the selective SGLT2 inhibitor Ipragliflozin L-Proline (generic name, brand nam...

Tuesday 9th January 2018

Application for Marketing Approval Submitted for Bispecific CD19-directed CD3 T Cell Engager (BiTE®) Antibody Construct Blinatumomab for Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia in Japan (pdf 205KB)

Wednesday 20th December 2017

Astellas to Present at J.P. Morgan Healthcare Conference (pdf 178KB)

Tuesday 12th December 2017

Astellas Announces First Clinical Data from Phase I Study of Gilteritinib in Combination with Intensive Chemotherapy in Patients Newly Diagnosed with Acute Myeloid Leukemia

Wednesday 6th December 2017

Astellas, the Institute of Medical Science of the University of Tokyo, Chiba University, and Asahi Kogyosha Enter into Collaborative Research Agreement on Rice-based Oral Vaccine "MucoRice"

Tokyo, December 6, 2017 - Astellas Pharma Inc. (Tokyo, President and CEO: Yoshihiko Hatanaka, “Astellas” ), the Institute of Medical Science, the University of Tokyo (Tokyo, Dean: Yoshinori Murakami, “IMSUT”), Chiba University (Chiba, President: Takeshi Tokuhisa, “Chiba University”), and ASAHI KOGYOSHA CO.,LTD. (Tokyo, CEO: Yasutomo Takasu, “Asahi Kogyos...

Friday 1st December 2017

Astellas Announces Personnel Change(pdf 155KB)

Astellas Acquires Mitobridge Under Existing Collaboration(pdf 359KB)

Thursday 30th November 2017

Astellas Submits a New Drug Application for Gonax® 12-Week Extended-Release Formulation for Treatment of Prostate Cancer in Japan (pdf 249KB)

Wednesday 29th November 2017

Astellas to Present New Data Exploring Gilteritinib in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients at the 2017 American Society of Hematology Annual Meeting (ASH) (pdf 396KB)

Quick Search


News Quicklinks